Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.52 |
| ▸ | ITGAL | P20701 | 1/20 | 0.52 |
| ▸ | SPR | P35270 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875489 | 0.89 | KDM4E (0.60) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL12875465 | 0.87 | RAB9A (0.63) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL12875461 | 0.87 | KDM4E (0.58) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL12875487 | 0.87 | KDM4E (0.76) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL12875511 | 0.87 | KDM4E (0.64) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL12875498 | 0.86 | RAB9A (0.71) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL1198595 | 0.86 | MEN1 (0.72) | KDM4EALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL14196468 | 0.85 | RAB9A (0.60) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL14196464 | 0.85 | MEN1 (0.57) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL1198783 | 0.84 | ITGB2 (0.71) | KDM4EALDH1A1RAB9AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| US-7358267-B2 | Bis-aryl thiazole derivatives | AMGEN INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358267-B2 | Bis-aryl thiazole derivatives | AMGEN INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20050215608-A1 | Bis-aryl thiazole derivatives | AMGEN INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2003002062-A2 | BIS-ARYL THIAZOLE DERIVATIVES | TULARIK INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | KDM4E 1877/4885ALDH1A1 1037/4885RAB9A 2507/4885 |
| US-20050215608-A1 | Bis-aryl thiazole derivatives | FABP4, PC, TXNRD2 | KDM4E 3696/4885ALDH1A1 842/4885RAB9A 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.